Posted by Michael Wonder on 02 Oct 2020
Farxiga granted breakthrough therapy designation in US for chronic kidney disease
2 October 2020 - Designation follows DAPA-CKD Phase 3 trial results in which Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease.
AstraZeneca’s Farxiga (dapagliflozin) has been granted breakthrough therapy designation in the US for patients with chronic kidney disease, with and without type 2 diabetes mellitus.
